Answers are grounded in this paper and cite their sources.
Reports refractory Kawasaki disease causing giant coronary aneurysms and thrombosis in an infant boy requiring infliximab, highlighting the need for biologic agents in persistent inflammation.
Giant coronary artery aneurysms that occur in 0.5 to 1% of patients with Kawasaki disease can be fatal if associated with thrombosis.Some patients may show persistent inflammation and fever despite treatment with repeated doses of intravenous immunoglobulin (IVIG), steroids, and aspirin.This report describes an infant boy with resistant Kawasaki disease who presented with extensive coronary artery involvement and coronary thrombosis.His inflammation was not controlled with multiple doses of IVIG, parenteral and oral steroids, or high-dose aspirin, and he finally needed infliximab, a monoclonal antibody against tumor necrosis factor alpha.
No takes yet. Share an insight, caveat, or question.
Anass et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: